These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9414600)

  • 1. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
    Watabe T; Okuda H; Ogura K
    Yakugaku Zasshi; 1997 Nov; 117(10-11):910-21. PubMed ID: 9414600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Ogura K; Kato A; Takubo H; Watabe T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi K; Watabe T; Ogura Y
    Drug Metab Dispos; 1997 Feb; 25(2):270-3. PubMed ID: 9029059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi Y; Watabe T
    Drug Metab Dispos; 1997 May; 25(5):270-3. PubMed ID: 9152608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].
    Watabe T; Ogura K; Nishiyama T
    Yakugaku Zasshi; 2002 Aug; 122(8):527-35. PubMed ID: 12187768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine.
    Ogura K; Nishiyama T; Takubo H; Kato A; Okuda H; Arakawa K; Fukushima M; Nagayama S; Kawaguchi Y; Watabe T
    Cancer Lett; 1998 Jan; 122(1-2):107-13. PubMed ID: 9464498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
    Yan J; Tyring SK; McCrary MM; Lee PC; Haworth S; Raymond R; Olsen SJ; Diasio RB
    Clin Pharmacol Ther; 1997 May; 61(5):563-73. PubMed ID: 9164418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.
    Nakayama H; Kinouchi T; Kataoka K; Akimoto S; Matsuda Y; Ohnishi Y
    Pharmacogenetics; 1997 Feb; 7(1):35-43. PubMed ID: 9110360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.
    Diasio RB
    Br J Clin Pharmacol; 1998 Jul; 46(1):1-4. PubMed ID: 9690942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
    Kanamitsu SI; Ito K; Okuda H; Ogura K; Watabe T; Muro K; Sugiyama Y
    Drug Metab Dispos; 2000 Apr; 28(4):467-74. PubMed ID: 10725316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH.
    Nishiyama T; Ogura K; Okuda H; Suda K; Kato A; Watabe T
    Mol Pharmacol; 2000 May; 57(5):899-905. PubMed ID: 10779372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
    Ashida N; Ijichi K; Watanabe Y; Machida H
    Biochem Pharmacol; 1993 Dec; 46(12):2201-7. PubMed ID: 8274153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
    Miyauchi S; Imaoka T; Okada T; Motoyama M; Kawaguchi T; Akiyama H; Odomi M
    Jpn J Pharmacol; 1996 Feb; 70(2):139-48. PubMed ID: 8866751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
    Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
    Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
    Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
    Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
    Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery of oral anti-cancer fluoropyrimidine agents.
    Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics.
    Watanabe M; Tateishi T; Takezawa N; Tanaka M; Kumai T; Nakaya S; Kobayashi S
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):250-4. PubMed ID: 11320669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.